EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Publicaciones (121) Publicaciones de EMILIO ESTEBAN GONZALEZ
2024
-
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782
Lung Cancer, Vol. 190
-
Concealed Inherited Cardiomyopathies Detected in Cardio-Oncology Screening
Journal of Clinical Medicine, Vol. 13, Núm. 1
-
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
Cancer Epidemiology Biomarkers and Prevention, Vol. 33, Núm. 3, pp. 419-425
-
“Inherited cardiovascular disease mindset” can identify concealed inherited conditions at cardio-oncology evaluation: An opportunistic screening.
International Journal of Cardiology, Vol. 401
2023
-
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3492-3500
-
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 24, Núm. 11, pp. 1252-1265
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Bilateral diffuse uveal melanocytic proliferation (BDUMP) as ocular toxicity from durvalumab in advanced renal carcinoma
European Journal of Cancer
2021
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397
-
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
BJU International, Vol. 126, Núm. 5, pp. 559-567
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517
2019
-
Deep sequencing reveals microRNAs predictive of antiangiogenic drug response
JCI Insight, Vol. 1, Núm. 10
-
Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease
Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508
-
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789
2018
-
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579
-
KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?
Annals of Oncology, Vol. 29, pp. ix164
-
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092